Medical news today: Tuesday, November 17, 2026
US flu deaths in children rise, a Cochrane review backs daily iron for anaemia, and the FDA approves giredestrant for selected breast cancers
Get tomorrow's issue in your inbox.
- 01
US flu activity rises above baseline as CDC reports two more child deaths
Source: Medical Xpress (CIDRAP)
Outpatient visits for influenza-like illness reached 3.2%, above the 2.9% national baseline, and CDC reported two child flu deaths this week, five so far this season, according to CIDRAP's summary of CDC FluView. CDC estimates at least 2.6 million flu cases, 36,000 hospital admissions and 2,100 deaths so far, and says an early rise does not necessarily mean a worse peak.
Why it mattersFlu means sick days, lost wages and doctor bills; a flu shot is often low-cost or covered by insurance, so getting it before the holidays can save money as well as illness. Readers outside the US should follow their own health authority's advice. More on Drug & device safety →
- 02
Cochrane review finds daily iron supplements cut iron-deficiency anaemia in children
Source: Medical Xpress (Cochrane)
A Cochrane review of 114 studies with more than 50,000 children and adolescents found daily oral iron probably reduces iron-deficiency anaemia compared with no treatment or placebo, with little to no effect on common illnesses such as cough or fever. Certainty was low or very low for several outcomes, and the authors say not every child needs daily iron.
Why it mattersIron tablets are among the cheapest medicines available, and in India they are given free to children and adolescents under the government's Anaemia Mukt Bharat programme. Get a blood test and a doctor's advice before buying supplements for a child; see our iron Q&A. More on Nutraceuticals & supplements →
- 03
EMA review of iron infusions moves to its next step, with no new safety decision yet
Source: European Medicines Agency (EMA)
The EMA's Article 31 referral timetable for parenteral iron-containing medicines records that updated rapporteur and co-rapporteur assessment reports were circulated to PRAC and CMDh on 17 November. The document is a procedural timetable; it does not announce a final PRAC recommendation, new contraindication or regulatory restriction.
Why it mattersIntravenous iron infusions cost far more than tablets and are used when tablets fail or are not suitable; this procedural update does not change how they are used today. Patients should not stop prescribed treatment based on it and can ask their doctor about the review. More on Approvals & regulatory →
- 04
US measles outbreaks led to over 100 infections in pregnancy and congenital cases, CDC researchers report
Source: MedPage Today
US measles outbreaks since 2025 have triggered more than 100 maternal measles infections during pregnancy, cases of congenital measles in infants and at least one likely case of paediatric meningoencephalitis, according to CDC researchers, MedPage Today reports.
Why it mattersMeasles vaccination is low-cost or free in most countries, while a hospital stay for a sick newborn can cost a family dearly. Anyone planning a pregnancy can ask their doctor to check their MMR vaccination status first. More on Infectious disease →
- 05
CBD works no better than placebo for severe behaviour problems in children, trial finds
Source: MedPage Today
In an Australian randomized trial of 132 children and teens with intellectual disability and severe behavioural problems, published in JAMA Pediatrics, purified CBD oil gave similar improvements to placebo over eight weeks, MedPage Today reports. Side effects were similar in both groups, and editorialists said other trials in autism also showed no benefit.
Why it mattersFamilies can spend a lot on CBD products marketed for behaviour; this trial is evidence that purified CBD is unlikely to be worth the money for this use. Talk to the child's doctor before starting or stopping any treatment. More on Journal papers →
- 06
Johnson & Johnson agrees to buy eye-drug developer Ollin for $2.2 billion upfront
Source: BioPharma Dive
Markets: J&J will acquire Ollin Biosciences for $2.2 billion upfront plus up to $1.1 billion in milestones for OLN324, an experimental drug for wet age-related macular degeneration and diabetic macular oedema, BioPharma Dive reports. Blackstone Life Sciences is providing $750 million for Phase 3 testing against Lucentis or Eylea.
Why it mattersEye injections for macular degeneration are among the costliest routine treatments for older adults; more competitors may eventually pressure prices, but OLN324 is still in trials and years from patients. Not investment advice. More on Obesity & metabolic →
Market news · Not investment advice
- 07
Bipartisan US bill would add up to 12 weeks of job-protected leave for NICU parents
Source: MedPage Today (AP)
A bipartisan group of US lawmakers introduced a bill to amend the Family and Medical Leave Act to give eligible workers up to 12 weeks of unpaid, job-protected NICU leave on top of existing parental leave, AP reports via MedPage Today. The bill must be reintroduced after the new Congress is seated in January. Walmart begins offering up to 12 extra weeks of NICU leave on Tuesday.
Why it mattersParents of NICU babies often burn their leave before the baby comes home, risking lost income or their job. The bill is unpaid leave and not yet law, so check your employer's own NICU or family-leave policy now.
- 08
FDA approves giredestrant with everolimus for selected ESR1-mutated advanced breast cancers
Source: US Food and Drug Administration (FDA)
The FDA approved oral giredestrant (Wilserdly) with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer after specified endocrine-therapy progression or recurrence. In the ESR1-mutated subgroup of the randomized evERA trial, median progression-free survival was 10 months versus 5.5 months with physician's-choice endocrine therapy plus everolimus (hazard ratio 0.38); overall-survival data were immature. FDA also authorized the FoundationOne Liquid CDx companion diagnostic. The FDA page lists stomatitis, rash, fatigue, diarrhoea, musculoskeletal pain, pneumonitis and nausea among common adverse reactions, and notes warnings for bradycardia and embryo-fetal toxicity.
Why it mattersNew targeted cancer drugs usually launch at high prices, and this one needs a companion blood test to show who qualifies, so patients and insurers should check coverage for both the drug and the test. It applies only to a biomarker-defined group, and overall survival data are not yet mature. More on Approvals & regulatory →
- 09
EU authorises oral pill povorcitinib for hard-to-treat hidradenitis suppurativa
Source: European Medicines Agency (EMA)
The EMA's public assessment page, first published on 16 November, records that Povofortay (povorcitinib) received an EU-wide marketing authorisation on 12 November for adults with active moderate-to-severe hidradenitis suppurativa who have responded inadequately to, are intolerant of or cannot receive anti-TNF therapy. The EPAR describes two main studies involving 1,227 adults and notes that the medicine is under additional monitoring. Risk-management materials address serious infections, shingles, cancer, cardiovascular events and blood clots.
Why it mattersAn oral option could mean fewer clinic visits than injectable treatments for some patients in the EU, but price and reimbursement are decided country by country. The medicine is under additional monitoring for known JAK-inhibitor risks such as serious infections and blood clots. More on Approvals & regulatory →
- 10
Helus reports positive Phase 3 topline results for psychedelic depression candidate HLP003
Source: Helus Pharma (company-reported topline results)
Helus reported topline results from the randomized, double-blind, placebo-controlled APPROACH study of adjunctive HLP003 (deuterated psilocin) in 222 adults with moderate-to-severe major depressive disorder who continued stable antidepressant treatment. The company reported a placebo-adjusted MADRS difference of 7.6 points at week 6 and 7.0 points at week 12. It also reported three HLP003 treatment-related serious adverse events and said no new safety signals were identified. These are sponsor-reported topline findings; the candidate remains investigational and the release is not a peer-reviewed full trial report or a regulatory approval.
Why it mattersPsychedelic-assisted treatments may eventually be costly and require supervised sessions, so even a positive result is years away from affordable everyday access. These are company-reported topline results with three treatment-related serious adverse events; the drug is not approved. More on Approvals & regulatory →
More recent digests
- Wednesday, November 18, 2026White House pulls its FDA nominee, the US loses measles elimination status, and FDA offers to share its approval reviews with other regulators
- Monday, November 16, 2026Teen tirzepatide trial cuts BMI, US flu season starts early, and the FDA rejects Summit's lung cancer drug
- Sunday, November 15, 2026WHO issues first type 1 diabetes guidance for adults and children; JAMA reports a possible CTE blood biomarker; MP flags mercury creams
- Saturday, November 14, 2026FDA approves a weekly self-injected myasthenia gravis drug; US measles deaths rise; India enforces lower cancer-drug prices
- Friday, November 13, 2026WHO reports persistent TB burden; JAMA publishes new oncology and neonatal sepsis trials; MHRA flags a packaging defect
- Thursday, November 12, 2026WHO reports continuing Ebola emergency and African regulatory advances; FDA approves first FXIa inhibitor for secondary stroke prevention
- Wednesday, November 11, 2026FDA approves pimicotinib; GLP-1 eye warning and two device alerts; WHO updates TB resistance catalogue
Free daily email
The day's approvals, safety signals and trials, in five minutes.
Join the list with just your email. You can also follow the RSS feed.
